Research programme: angiogenesis inhibitors - CGI Pharmaceuticals

Drug Profile

Research programme: angiogenesis inhibitors - CGI Pharmaceuticals

Alternative Names: ASKA EphB4; Cancer therapeutics - CGI Pharmaceuticals; EphB4 inhibitors - CGI Pharmaceuticals; Multiplex angiogenesis inhibitors - CGI Pharmaceuticals

Latest Information Update: 23 Sep 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CGI Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 25 Jul 2007 This programme is still in active development
  • 10 Aug 2005 Cellular Genomics is now called CGI Pharmaceuticals
  • 20 Jul 2005 CGI Pharmaceuticals has selected CGI 1842 as its lead candidate
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top